Recruitment commenced for EMD-RX5 Phase 1 Study
Filed with ASX · · 3 pages · English
● The Phase 1, 2-way cross-over clinical trial of EMD-RX5 will assess the safety and bioavailability of EMD-RX5 compared to Epidyolexin 12 healthy human volunteers who will receive both cannabinoid treatments; Epidyolex is the only CBD-only medicine formally registered with the TGA and the FDA ● EMD-RX5 is a proprietary, highly bioavailable oral formulation of ultra-pure CBD, anticipated to suppor
Earlier from Emyria
- Ethics approval received for EMD-RX5 Phase 1 Study
- Emyria grows its novel MDMA-analogue library
- Application for quotation of securities - EMD
- Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD
- Notification regarding unquoted securities - EMD
Later from Emyria
- Emyria launches second ultra-pure CBD capsule
- Broker Briefing Presentation
- Further positive MDMA analogue screening results received
- EMD-RX5 demonstrates excellent safety and bioavailability
- Emyria expands MDMA analogue program with UWA
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria